EP4013468A1 - Bone marrow derived cell bone graft material - Google Patents
Bone marrow derived cell bone graft materialInfo
- Publication number
- EP4013468A1 EP4013468A1 EP20760786.2A EP20760786A EP4013468A1 EP 4013468 A1 EP4013468 A1 EP 4013468A1 EP 20760786 A EP20760786 A EP 20760786A EP 4013468 A1 EP4013468 A1 EP 4013468A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bone
- bone graft
- scaffold
- cells
- graft material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000463 material Substances 0.000 title claims abstract description 221
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 160
- 210000001185 bone marrow Anatomy 0.000 title claims abstract description 34
- 210000004027 cell Anatomy 0.000 claims abstract description 131
- 238000000034 method Methods 0.000 claims abstract description 42
- 239000007943 implant Substances 0.000 claims abstract description 40
- 238000011282 treatment Methods 0.000 claims abstract description 39
- 208000020084 Bone disease Diseases 0.000 claims abstract description 17
- 206010031264 Osteonecrosis Diseases 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 238000001356 surgical procedure Methods 0.000 claims abstract description 13
- 206010061363 Skeletal injury Diseases 0.000 claims abstract description 10
- 208000014674 injury Diseases 0.000 claims abstract description 7
- 239000003826 tablet Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 239000001506 calcium phosphate Substances 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 210000005087 mononuclear cell Anatomy 0.000 claims description 9
- 238000010899 nucleation Methods 0.000 claims description 9
- 206010065687 Bone loss Diseases 0.000 claims description 8
- 210000002536 stromal cell Anatomy 0.000 claims description 8
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 8
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 7
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 6
- 208000010392 Bone Fractures Diseases 0.000 claims description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 5
- 235000011010 calcium phosphates Nutrition 0.000 claims description 5
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 5
- 239000004626 polylactic acid Substances 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 208000030016 Avascular necrosis Diseases 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 229920002988 biodegradable polymer Polymers 0.000 claims description 3
- 239000004621 biodegradable polymer Substances 0.000 claims description 3
- 230000008468 bone growth Effects 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000037873 arthrodesis Diseases 0.000 claims description 2
- 239000000316 bone substitute Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 208000037921 secondary disease Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 210000001956 EPC Anatomy 0.000 claims 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract description 57
- 238000002360 preparation method Methods 0.000 abstract description 27
- 230000006378 damage Effects 0.000 abstract description 9
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 230000010478 bone regeneration Effects 0.000 abstract description 2
- 238000000968 medical method and process Methods 0.000 abstract description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 22
- 238000010257 thawing Methods 0.000 description 16
- 238000005138 cryopreservation Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 239000011148 porous material Substances 0.000 description 12
- 238000007710 freezing Methods 0.000 description 11
- 230000008014 freezing Effects 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 230000002503 metabolic effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 9
- 238000002513 implantation Methods 0.000 description 9
- 230000011164 ossification Effects 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 8
- 238000012258 culturing Methods 0.000 description 7
- 210000000963 osteoblast Anatomy 0.000 description 7
- 210000002997 osteoclast Anatomy 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000002577 cryoprotective agent Substances 0.000 description 6
- 239000012595 freezing medium Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 6
- 229910052753 mercury Inorganic materials 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000005245 sintering Methods 0.000 description 4
- 102100037241 Endoglin Human genes 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000008108 Osteoprotegerin Human genes 0.000 description 3
- 108010035042 Osteoprotegerin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000007783 nanoporous material Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 3
- 230000002138 osteoinductive effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229910001868 water Inorganic materials 0.000 description 3
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108090000031 Hedgehog Proteins Proteins 0.000 description 2
- 102000003693 Hedgehog Proteins Human genes 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 208000002607 Pseudarthrosis Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 1
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 208000018035 Dental disease Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000264877 Hippospongia communis Species 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102100023068 Protein kinase C-binding protein NELL1 Human genes 0.000 description 1
- 101710097762 Protein kinase C-binding protein NELL1 Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108010043267 Sp7 Transcription Factor Proteins 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 102100032317 Transcription factor Sp7 Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- TZSMWSKOPZEMAJ-UHFFFAOYSA-N bis[(2-methoxyphenyl)methyl] carbonate Chemical compound COC1=CC=CC=C1COC(=O)OCC1=CC=CC=C1OC TZSMWSKOPZEMAJ-UHFFFAOYSA-N 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000004068 calcium phosphate ceramic Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 239000005548 dental material Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000016574 developmental growth Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007792 gaseous phase Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000000278 osteoconductive effect Effects 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009475 tablet pressing Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the invention pertains to the use of bone marrow derived cells (BMDC) except mesenchymal stem cells (MSC) in the treatment of bone disorders or injuries.
- BMDC bone marrow derived cells
- MSC mesenchymal stem cells
- the invention provides BMDC and preparations of specifically pooled BMDC for use in the manufacturing of bone graft material for implanting into or attaching to bones in order to enhance bone regeneration after surgery or injury, or to treat various bone disorders, such as osteonecrosis.
- the invention provides bone graft material, a method for its production, bone graft implants, and medical methods and uses of the inventive products.
- Bone formation and degradation are tightly regulated by growth factor signalling between osteoblasts that are responsible for bone formation and osteoclasts that are responsible for bone re-absorption.
- Coupling bone formation by osteoblasts with degradation by osteoclasts has recently become a topic of intense study; with the list of growth factors identified as coupling factors expanding.
- Coupling bone formation with bone re-absorption requires the recruitment of osteoblasts and osteoclasts in parallel with the recruitment of their respective progenitor cells.
- Osteoblasts derive from mesenchymal stem cell (MSC) while osteoclasts derive from monocytes that are a part of the myeloid-lineage; however, it remains unknown how MSC or monocytes migrate from their niche in the bone marrow to sites of new bone formation.
- MSC mesenchymal stem cell
- monocytes also migrate from their bone marrow niche to the endosteal surface; where they subsequently differentiate into osteoclasts that re-absorb bone.
- Growth factors known to regulate bone formation include TGF -, BMP- and the canonical Wnt-ligands.
- Osteoclast formation from monocyte precursors and bone re absorption are regulated through the expression of MSCF, OPG and RANK-ligand.
- osteoclast activity is also regulated by the expression of the TGF -, BMP- and the non-canonical Wnt-ligands.
- TGF -, BMP- and the Wnt-ligands promote bone formation and re-absorption. The maintenance of healthy bone requires constant remodelling, in which bone is made and destroyed continuously.
- MSCs are stromal cells that are plastic-adherent and able to differentiate into osteoblasts, chondroblasts, and adipocytes. They express biomarkers including CD73, CD90, and CD105, and they must not express CD14 or CDub, CD34.
- MSC can be derived mainly from bone marrow, but also umbilical cord blood or from other sources. In particular bone marrow derived MSC have been most extensively studied both in preclinical and clinical experiments: the effects of such MSC in fracture healing, spinal fusion, and osteonecrosis have been demonstrated (Su P, et al, Int J Mol Sci. 2018 Aug 9;i9(8)).
- the invention pertains to bone graft material for use in the treatment of a subject, comprising a scaffold material and a biological cell material, wherein the biological cell material comprises cell material genetically allogenic to the subject; wherein the bone graft material and the biological cell material does not comprise MSCs.
- the invention pertains to bone graft implant, comprising a scaffold material and a biological cell material, wherein the bone graft implant is in the form of an implantable tablet having a height of l to 10 mm, preferably 3 to 5 mm, and/or a diameter of 1 to 15 mm, preferably 5 to 8 mm; wherein the bone graft implant does not comprise MSCs.
- the invention pertains to a method for producing cryopreserved bone graft material, and wherein the bone graft material does not comprise MSCs comprising the steps of
- the invention pertains to a method of producing a bone graft implant, the method comprising the step of compressing a bone graft material recited in any one of the preceding claims into a tablet, preferably having a height of 1 to 10 mm, preferably 3 to 5 mm, and/or a diameter of 1 to 15 mm, preferably 5 to 8 mm; and wherein the bone graft material does not comprise MSCs.
- the invention pertains to a therapeutic kit, the kit not comprising MSCs, but comprising
- a first container comprising a scaffold material recited in any one of the preceding aspects
- a second container comprising a biological cell material recited in any one of the preceding aspects.
- the invention pertains to a bone marrow derived cell (BMDC), or a BMDC preparation for use in the treatment of a disease, wherein the treatment comprises the administration of the BMDC, or the BMDC preparation, to a subject in need of the treatment by adhering the BMDC or BMDC preparation to a bone graft material to obtain an BMDC -bone graft material, and implanting or attaching the BMDC -bone graft material into/to one or more bone(s) of the patient; and wherein the BMDC do not comprise MSC.
- BMDC bone marrow derived cell
- the invention pertains to a use of a BMDC, or a BMDC preparation, in the manufacture of a medicament, preferably a bone graft material, for use in the treatment of a bone injuiy or disorder.
- the invention pertains to bone graft material, comprising a scaffold material and a biological cell material, wherein the biological cell material comprises cell material genetically allogenic to the subject to be treated with the bone graft material; and wherein the bone graft material does not comprise MSC.
- the bone graft material of the invention is for use in the treatment of a subject.
- BMDCs bone marrow derived cells
- CD117+ cells including hematopoietic stem cells, endothelial progenitor cells and other progenitor cells, and does not include or comprise mesenchymal stem (or stromal) cells (MSC).
- MSC mesenchymal stem
- EPCs endothelial progenitor cells
- cell material as used in context of the present invention shall in particular pertain to materials comprising biological cell material, such as living or dead cells, preferably living cells, as well as any secreted factors derived from the culturing of such cells. In certain preferred embodiments, however, the present invention pertains to cell material comprising living biological cells.
- biological cell in context of the invention shall preferably refer to a mammalian cell, most preferably a human cell. Certain embodiments of the invention pertain to cell compositions that do not comprise mesenchymal stromal cells.
- the term "mesenchymal stromal cell” is a multipotent stromal cell that can differentiate into a variety of cell types, including, but not limited to osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells). These cells are also known as “mesenchymal stem cells” due to their multipotency. This biologically important cell population is able to support haematopoiesis, can differentiate along mesenchymal and non-mesenchymal lineages in vitro, is capable of suppressing alloresponses and appears to be non -immunogenic.
- Preferred cells used as cell material according to the invention are hematopoietic stem cells or EPCs, or similar progenitor cells derived from bone marrow.
- the MSC according to the invention is in some preferred embodiments provided as a monogenic composition, therefore, such composition comprises cells of only one genetic background (or derived from one single donor subject).
- Other embodiments, which might be preferred in context of the invention then pertain to a cell preparation that comprises BMDC derived from multiple genetically distinct donor subjects.
- Preferred BMDC preparations are those which are prepared correspondingly as MSCs according to the methods described in PCT/EP2015/066083 (published as WO 2016/008895; disclosed herein by reference in its entirety, and specifically the method for generating MSC preparations comprising a step of pooling MSC from more than one genetically distinct donor before MSC isolation from such cell pool).
- BMDC bone marrow mononuclear cell
- the cell material is allogenic to the subject treated with the bone graft material of the invention.
- allogenic or allogeneic refers to cells, tissues or organs that are not genetically identical or are derived from a non-genetically identical source to the transplant recipient (e.g., a non-related donor), especially with respect to antigens or immunological reactions.
- Such cells, tissues or organs are called allografts, allogeneic transplants, homografts or allotransplants.
- the invention in addition pertains to bone graft material that comprises scaffold material that is suitable for implantation into or attachment onto a mammalian bone.
- scaffold material is intended to refer to a composition that is capable of forming a scaffold, i.e. a pre-scaffold material.
- the scaffold material may comprise a composition that is capable of setting into a scaffold.
- the scaffold material itself may or may not have a structure of a scaffold until the scaffold material has formed the scaffold according to the methods herein.
- Reference to "a composition that is capable of forming a scaffold” may include the capability to form a scaffold with no further intervention/process steps or components.
- reference to "a composition that is capable of forming a scaffold” may include the capability to form a scaffold following further intervention/process steps according to the invention herein and/or following addition of components according to the invention herein.
- the term “scaffold” (may be interchanged with the term “matrix”) is understood to mean a solid mass of material having a 3 -dimensional structure, which may for example be suitable to support cells.
- the scaffold maybe porous, having interconnected pores or gaps.
- the scaffold material is synthetic or natural, preferably wherein the scaffold material comprises calcium phosphate, preferably a-, or b- tricalciumphosphate (TCP), or comprises polylactic acid or polycarpolactone (or other biodegradable polymer), or a mixture of these materials.
- Natural scaffold material is for example obtained from bones or dental material.
- Naturally-derived bone scaffold materials are usually prepared by acid extraction of most of the mineralized component to result in so called demineralized bone matrix (DBM).
- DBM demineralized bone matrix
- Examples for naturally-derived materials are Bio-Oss® of the mineral portion of bovine bone or Algipore® a porous calcium phosphate material of algae.
- Autologous (or allogentic) bone is an ideal source of graft material, not only due to its biocompatibility, but also because natural bone grafts facilitate reossification of the defect site by promoting or conducting ingrowth of the patient's own bone tissue to the defect site. Methods for obtaining such material are well known to the person of skill in the art.
- An additional preferred source of natural bone scaffold material is the use of heat-inactivated spongiosa which is prepared by removing cartilage from a femoral head and heating it to more than 6o°C, preferably to more than 8o°C, preferably about 90°C, for more than to minutes (preferably about an hour).
- the aforementioned b-TCP is one crystal form of a composition represented by Ca 3 (P0 4 ) 2 , which is a biocompatible compound that is stable at normal temperature.
- b- TCP commercially available b-TCP powders and b-TCP blocks, for example, b-TCP blocks to be used as scaffold material may be used, or the b-TCP can be produced by a publicly known method (Japanese unexamined Patent Application Publication No. 2004-26648, etc.) or from an a-TCP powder (Japanese unexamined Patent Application Publication No. 2006-89311, etc.).
- the b-TCP composition of the present invention may be a b-TCP composition substantially composed of b-TCP or a b-TCP composition produced by mixing in a surfactant, water and so on
- the b-TCP composition may be a b-TCP powder obtained by processing a b- TCP block into particles or granules
- the b-TCP composition is preferably a polycrystalline, high-strength and high-density b-TCP dense body having a low porous rate obtained by densificating a b-TCP powder by tablet pressing or after defoaming by sintering, and among such b-TCP dense bodies, one having a porous rate of 50% or more is preferable.
- a b-TCP dense body refers to b-TCP having a porous rate of 50% or more. Also in the present invention, powders, particles, and granules all indicate the granular form, and there is no substantial distinction among them. Pores in the b-TCP dense body are determined according to the size and number of spaces between the particles of the polycrystal.
- the porous rate of b-TCP can be measured by using a micro CT (Bertoldi S, Fare S, Tanzi MC. Assessment of scaffold porosity: the new route of micro-CT. J Appl Biomater Biomech. 2011 Sep-Dec;9(3):i65-75- doi: 10.5301/JABB.2011.8863. Review) a mercury intrusion method, in which pressure is applied to force mercury into a pore and the specific surface area and pore distribution are obtained from the pressure applied and the amount of mercury intruded, or from the density using a calibration curve.
- the porous rate P can also be measured using, for example, the ACCUPYC 1330 series (the product of Shimadzu Corporation).
- the porous rate in the b-TCP block as measured by the mercury intrusion method is preferably 50 to 90%, more preferably 60 to 85%, and even more preferably 70 to 80%.
- a b-TCP powder having a particle diameter of 75 to 105 pm can be produced by pulverizing a b-TCP block, and the porous rate of each powder thus produced as measured by the mercury intrusion method is preferably 50 to 90%, more preferably 55 to 85%, and even more preferably 57 to 80%, and a preferable average porous rate is 60 to 70%.
- a b-TCP microgranule having a particle diameter of 25 pm or less can also be produced by pulverizing a b-TCP block into particles.
- the porous rate of the b-TCP microgranule thus produced as measured by the mercury intrusion method is preferably 50% or more, more preferably 50% to 90%.
- the b-TCP dense body can include a b-TCP powder, particle, granule, tablet, and columnar body having a porous rate of 50% or more.
- These b-TCP dense bodies may consist exclusively of b-TCP or comprise b-TCP as scaffold for the MSC seeded on the material as active ingredient, as well as other components.
- densifi cation of a b-TCP powder by sintering is performed by sintering preferably at above 600 °C to 2000 °C, more preferably at 750 to 1500 °C, and even more preferably at 900 to 1300 °C, and preferably for 1 to too hours, more preferably for 10 to 80 hours, and even more preferably for 20 to 50 hours.
- sintering can be divided into multiple operations and performed at a plurality of different temperatures.
- a rod shaped b-TCP dense body can also be produced by the following method.
- a slurry is prepared by mixing calcium hydrogen phosphate, calcium carbonate, and water at an appropriate ratio, and the slurry thus prepared is allowed to undergo reaction while grinding, followed by drying. Subsequently, the solid material obtained after drying is pulverized and calcined to give a b-TCP powder.
- the b-TCP powder thus obtained is formed into a columnar body by compression forming. The resulting compression-formed columnar body is sintered at 600 °C to 1300 °C for about 20 hours.
- the scaffold material is a nanoporous material.
- nanoporous generally refers to a porous material (i.e. a calcium phosphate ceramic) whose average pore diameter is in the nanometer range (typically between 1 to 1000 nm). More preferably, the pores of the nanoporous material of the invention are communicating nanopores, which preferably are pores which are interconnected via channels. Such communicating pores preferably have a degree of porosity and interconnection that there is a channel connection from one side of the graft to the other.
- a porosity according to the invention is preferably a porosity of 50% - 90%, preferably of 60% - 70%; and/ or wherein the nanopores have an average diameter of 50 - 600 pm, preferably of too - 500 pm; and/ or wherein the nanopores are communicating nanopores.
- the scaffold material is preferably not a decellularized tissue matrix obtained from natural, such a xenogeneic (non-human) tissues.
- the term “decellularized” or “decellularization” as used herein refers to a biostructure (e.g., a tissue or an organ, or part of an organ), from which the cellular content has been removed leaving behind an intact acellular infra-structure mainly composed of collagens.
- the bone graft material is in the form of an implantable tablet, preferably a tablet having cylindrical shape (rod-shaped).
- cylindrical shape refers to any geometrical shape having the same cross section area throughout the length of the geometrical shape.
- the cross section of a cylinder within the meaning of the present invention may have any two dimensional shape, for example the cross section may be circular, oval, rectangular, triangular, angular or star shaped.
- the pharmaceutical compositions described herein have a cylindrical shape, wherein the end(s) are optionally tapered.
- a bone graft material according to the invention is a tablet having a height of 1 to 10 mm, preferably 3 to 5 mm, and/or a diameter of 1 to 15 mm, preferably 5 to 8 mm.
- the tablet of the invention with the herein disclosed dimensions showed surprisingly improved effects for the performance of the MSC during the treatment.
- the “length” refers to the dimension of the longest axis of the tablet and the “height” refers to the dimension of the longest axis in the largest plane of the tablet. The diameter therefore refers to the axis perpendicular to the height.
- the bone graft material of the invention is cryopreserved, and thus optionally requires thawing immediately before surgical insertion or attachment to the bone of a patient.
- cryopreservation refers to the process of cooling and storing biological cells, tissues, or organs at low temperatures to maintain their viability.
- cryopreservation can be the technology of cooling and storing cells at a temperature below the freezing point (e.g., -20 °C or colder, -80 °C or colder, or the like) that permits high rates of survivability of the cells upon thawing.
- the biological material seeded onto the scaffold material is ideally cryopreserved in order to provide an off-the-shelf product for implantation.
- the invention pertains to bone graft implant, comprising a scaffold material and a biological cell material, wherein the bone graft implant is in the form of an implantable tablet having a height of 1 to 10 mm, preferably 3 to 5 mm, and/or a diameter of 1 to 15 mm, preferably 5 to 8 mm; the bone graft material not comprising MSC.
- the bone graft implants may be made from allograft, autograft, xenograft, cortical, cancellous, cartilage, and combinations of, synthetic HA, B-TCP, Ceramic, PLA, PLGA, PLLA or other such materials and may be incorporated with growth factors, plasma (e.g., platelet rich plasma), platelets (e.g., intact platelets), cells, peptides or other such materials.
- growth factors e.g., platelet rich plasma
- platelets e.g., intact platelets
- cells peptides or other such materials.
- the bone graft implants are cylinders, rectangular, trapezoidal, flat, convex, concave, and may have a channel on one or both sides for easy placement against a patient's bone or for buttressing against a bone.
- the bone graft implants may be trimmed to size and snapped onto a rod by press fit or by means of sutures.
- the bone graft implant biological cell material comprises living cells, preferably allogenic or autologous. More preferably the biological cell material is the biological cell material as described herein for the first aspect of the invention.
- the bone graft material, cellular composition or other compounds, materials and composition described herein in the various aspects of the invention preferably do not comprise added, and preferably immobilized, bone growth factors or cytokines.
- Such growth factors and cytokines are often added in order to render cells in bone graft material osteo-inductive.
- the materials of the present invention in all aspects and embodiments thereof preferably do not require such addition of osteo-inductive cytokines or growth factors since the cellular compositions of the invention are inherently osteo-inductive.
- Such cytokines include bone morphogenic protein (BMP), Indian hedgehog (IHH), transforming growth factor b (TGF3); bone morphogenetic proteins (BMPs); fibroblast growth factors (FGFs); Wnt ligands and b-catenin; insulin-growth factors (IGFs); collagen-i; Runx2; osteopontin; osterix; vascular endothelial growth factor (VEGF); platelet derived growth factor (PDGF); osteoprotegerin (OPG); NEL-like protein 1 (NELL-i ); or a mixture thereof.
- BMP bone morphogenic protein
- IHH Indian hedgehog
- TGF3 transforming growth factor b
- BMPs bone morphogenetic proteins
- FGFs fibroblast growth factors
- IGFs insulin-growth factors
- collagen-i Runx2
- osteopontin osterix
- VEGF vascular endothelial growth factor
- PDGF platelet derived growth factor
- the bone graft implant according to the invention is preferably cryopreserved.
- the invention pertains to a method for producing or manufacturing a cryopreserved bone graft material; the bone graft material not comprising MSCs, comprising the steps of
- cryopreservation medium is used in order to minimize the loss of cell material during the process.
- cryopreservation medium or "ciyoprotectant” is a substance that is used to protect eukaryotic cells (and also tissues, organs) from freezing damage. Further, the cryopreservation agent or ciyoprotectant may protect the eukaryotic cells (and also tissues or organs) from cold and heat shock, dehydration, and cryo-toxicity during cryopreservation. The cryopreservation agent or cryoprotectant may be cell penetrating or non-penetrating.
- cryoprotectants include glycerol, DMSO (dimethyl sulfoxide), propylene glycol, ethylene glycol, acetamide, and methanol.
- DMSO dimethyl sulfoxide
- cryoprotectants have some disadvantages in that they can induce protein denaturation at higher temperature and cause cryoprotectant toxicity in cellular systems (like tissues and organs).
- the toxicity of the cryoprotectants is a major limitation to successful cryopreservation of eukaryotic cells.
- DSMO is a preferred cryoprotectant for use in accordance with the present invention.
- the cryopreservation is performed at -15 °C or less, preferably is -20 °C or less, preferably less than -50 °C (about -70 °C or -80 °C); preferably the cryopreservation comprises a step of freezing at a freezing temperature of less than -20 °C, such as -40 °C or less, and subsequent storing of at temperatures higher than the freezing temperature.
- the scaffold material for us in the process of the invention is in granulate form, preferably wherein the granules have an average size of 0.1 to 3 mm, preferably 0.5 to 3 mm, more preferably 0.7 to 2.8 mm, more preferably 1.4 to 2.8 mm.
- the scaffold material is already provided in the form of an implantable body, such as a tablet or rod, preferably in cylindrical shape.
- the biological cell material is seeded on the scaffold material in accordance with some embodiments of the invention in a density of at least 0.1 x to 6 cells per mL scaffold material, preferably of at least 0.5 x 10 6 cells per mL scaffold material, more preferably of about 1 x 10 6 cells per mL scaffold material.
- the invention pertains to a method of producing a bone graft implant, the method comprising the step of compressing a bone graft material recited in any one of the preceding claims into a tablet, preferably having a height of 1 to 10 mm, preferably 3 to 5 mm, and/or a diameter of 1 to 15 mm, preferably 5 to 8 mm; wherein the bone graft implant does not comprise MSCs.
- the invention pertains to a therapeutic kit, the kit not comprising MSCs; comprising
- a first container comprising a scaffold material recited in any one of the preceding aspects
- the present invention further provides a therapeutic kit comprising separate containers of the biological cell material and the scaffold material.
- a therapeutic kit comprising separate containers of the biological cell material and the scaffold material.
- it is intended to mix the cell material directly with the scaffold material before medical use. For example, either the biological cell material is immediately combined with the scaffold material before surgical implantation, or alternatively, before the combination the biological cell material is expanded by in-vitro culturing to provide higher cell numbers before application.
- the first and the second container may have any form suitable for packaging their respective materials.
- the container are formed such to allow a direct mixing of the content of the first container with the content of the second container to obtain the final product for use in the treatment. Syringes are one example of such containers.
- the therapeutic kit of the invention may comprise additional components useful for realizing a medical treatment of the invention. Buffers, media, or instructions for use are non limiting examples of such additional components.
- the invention pertains to a bone marrow derived cell (BMDC), or a BMDC preparation for use in the treatment of a disease, wherein the treatment comprises the administration of the BMDC, or the BMDC preparation, to a subject in need of the treatment by adhering the BMDC or BMDC preparation to a bone graft material to obtain an BMDC -bone graft material, and implanting or attaching the BMDC -bone graft material into/to one or more bone(s) of the patient; wherein the BMDC do not comprise MSC.
- BMDC bone marrow derived cell
- the invention pertains to a use of a BMDC, or a BMDC preparation, in the manufacture of a medicament, preferably a bone graft material, for use in the treatment of a bone injury or disorder.
- a bone injury or disorder preferably selected from aseptic bone necrosis (spontaneous or therapy induced), bone fractures, fractures with secondary dislocation, pseudo- arthrosis, and reduced and delayed bone build-up.
- Bone disorder treatable by the invention are any condition affecting the development and/or the structure of the skeletal system.
- Bone disorders can include any disorder that results in an imbalance in the ratio of bone formation to bone resorption such that, if unmodified, a subject will exhibit less bone than desirable, or a subject's bones will be less intact and coherent than desired.
- Bone disorders may refer to disorders, diseases, conditions or traumas of bone, such as fractures, osteoporosis, osteoarthritis, or cancers.
- a bone disorder may result from fracture, from surgical intervention or from dental or periodontal disease. These diseases have a variety of causes and symptoms known in the art. Bone disorders can affect people of all ages, from newborns to older adults. However, certain age groups are more likely to have certain types of disorders.
- the uses and methods according to the above aspects may in certain preferred embodiments comprise a step of culturing the BMDC, or BMDC preparation and in particular the BMDC comprised in the graft material of the invention, before implantation.
- the uses and methods of the invention comprise a step of culturing for at least 6h, preferably at least i2h, more preferably at least i8h, more preferably at least 24h, even more preferably at least 36h and most preferably at least 48h or more.
- the indicated culture times are commenced immediately after thawing the frozen BMDC preparation and before implantation. Maximum culture times are up to 96h, or less, for example 7h - most preferred is a culturing time of 24 to 72h, or for about 48I1.
- a method for thawing a bone graft material according to the invention and preparing the bone graft material for implantation comprising a step of culturing the BMDC comprised in the bone graft material for at least 6h, preferably at least i2h, more preferably at least i8h, more preferably at least 24h, even more preferably at least 36I1 and most preferably at least 48I1 or more.
- the indicated culture times are commenced immediately after thawing the frozen BMSC preparation and before implantation. Maximum culture times are up to 96I1, or less, for example 7I1 - most preferred is a culturing time of 24 to 72h, or for about 48I1.
- the term “comprising” is to be construed as encompassing both “including” and “consisting of’, both meanings being specifically intended, and hence individually disclosed embodiments in accordance with the present invention.
- “and/or” is to be taken as specific disclosure of each of the two specified features or components with or without the other.
- a and/or B is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein.
- the terms “about” and “approximately” denote an interval of accuracy that the person skilled in the art will understand to still ensure the technical effect of the feature in question.
- the term typically indicates deviation from the indicated numerical value by ⁇ 20%, ⁇ 15%, ⁇ 10%, and for example ⁇ 5%.
- the specific such deviation for a numerical value for a given technical effect will depend on the nature of the technical effect.
- a natural or biological technical effect may generally have a larger such deviation than one for a man-made or engineering technical effect.
- the specific such deviation for a numerical value for a given technical effect will depend on the nature of the technical effect.
- a natural or biological technical effect may generally have a larger such deviation than one for a man-made or engineering technical effect.
- Item 1 A bone graft material for use in the treatment of a subject, comprising a scaffold material and a biological cell material, wherein the biological cell material comprises cell material genetically allogenic to the subject, and wherein the biological cell material does not comprise MSC.
- Item 2 The bone graft material for use according to item 1, wherein the biological cell material comprises living cells.
- Item 3 The bone graft material for use according to item 1 or 2, wherein the biological cell material, and preferably the graft material is cryopreserved.
- Item 4 The bone graft material for use according to any one of items 1 to 3, wherein the biological cell material comprises cells derived from any source, or comprises bone marrow mononuclear cells (BMC).
- BMC bone marrow mononuclear cells
- Item 5 The bone graft material for use according to any one of items 1 to 4, wherein the biological cell material comprises living cells of one donor subject, preferably of more than two genetically distinct donor subjects, preferably from at least 3, 4, 5, 6, 7, 8. 9 or 10 or more genetically distinct donor subjects.
- Item 6 The bone graft material for use according to item 5, wherein the biological cell material is obtained from, or derived from, a pooled preparation of bone marrow samples, or bone marrow mononuclear cell fractions, of the genetically distinct donors, in accordance with a method as described in WO 2016/008895.
- Item 7 The bone graft material for use according to any one of items 1 to 6, wherein the treatment comprises surgical insertion or attachment of the bone replacement material to a bone of the subject.
- Item 8 The bone graft material for use according to any one of items 1 to 7, wherein the treatment is for promoting bone growth or healing, such as for example to treat a bone injury or disorder selected from bone fracture, bone trauma, arthrodesis, a bone deficit condition associated with post-traumatic bone surgery, post-prosthetic joint surgery, post-plastic bone surgery, post-dental surgery, bone chemotherapy treatment, congenital bone loss, post traumatic bone loss, post-surgical bone loss, post infectious bone loss, allograft incorporation or bone radiotherapy treatment, and preferably in the treatment of osteonecrosis (avascular necrosis (AVN)).
- avascular necrosis Avascular necrosis
- Item 9 The bone graft material for use according to item 8, wherein the osteonecrosis is a secondary disease caused by corticosteroid treatment, trauma, alcohol, sickle cell disease, leukaemia or other known causes of osteonecrosis, or is idiopathic osteonecrosis.
- Item 10 The bone graft material for use according to any one of items 1 to 9, wherein the biological cell material is adsorbed on the scaffold material.
- Item 11 The bone graft material for use according to any one of items 1 to 10, wherein the scaffold material is synthetic or natural, preferably wherein the scaffold material comprises calcium phosphate, preferably a-, or b-tricalciumphosphate (TCP), or comprises polylactic acid or polycaprolactone (or other biodegradable polymer), or a mixture of these materials.
- the scaffold material is synthetic or natural, preferably wherein the scaffold material comprises calcium phosphate, preferably a-, or b-tricalciumphosphate (TCP), or comprises polylactic acid or polycaprolactone (or other biodegradable polymer), or a mixture of these materials.
- Item 12 The bone graft material for use according to any one of items 1 to 11, wherein the scaffold material is a nanoporous material with a porosity of 50% - 90%, preferably of 60% - 70%; and/or wherein the nanopores have an average diameter of 50 - 600 pm, preferably of 100 - 500 pm; and/or wherein the nanopores are communicating nanopores.
- the scaffold material is a nanoporous material with a porosity of 50% - 90%, preferably of 60% - 70%; and/or wherein the nanopores have an average diameter of 50 - 600 pm, preferably of 100 - 500 pm; and/or wherein the nanopores are communicating nanopores.
- Item 13 The bone graft material for use according to any one of items 1 to 12, which is in the form of an implantable tablet, preferably a tablet having cylindrical shape.
- Item 14 The bone graft material for use according to item 13, wherein the tablet has a height of 1 to 10 mm, preferably 3 to 5 mm, and/ or a diameter of 1 to 15 mm, preferably 5 to 8 mm.
- Item 15 The bone graft material for use according to any one of items 1 to 14, which is cryopreserved and requires thawing immediately before surgical insertion or attachment.
- Item 16 A bone graft implant, comprising a scaffold material and a biological cell material, wherein the bone graft implant is in the form of an implantable tablet having a height of l to 10 mm, preferably 3 to 5 mm, and/or a diameter of 1 to 15 mm, preferably 5 to 8 mm.
- Item 17 The bone graft implant according to item 16, wherein the biological cell material comprises living cells, preferably allogenic or autologous.
- Item 18 The bone graft implant according to item 16 or 17, which is cryopreserved.
- Item 19 The bone graft implant according to any one of items 16 to 18, wherein the biological cell material comprises cells derived from any source, or comprises bone marrow mononuclear cells (BMC).
- Item 20 The bone graft implant according to any one of items 16 to 19, wherein the biological cell material comprises living cells of more than two genetically distinct donor subjects, preferably from at least 3, 4, 5, 6, 7, 8. 9 or 10 or more genetically distinct donor subjects.
- Item 21 The bone graft implant according to any one of items 16 to 20, wherein the scaffold material is the scaffold material recited in any one of items 1 to 15.
- Item 22 The bone graft implant according to any one of items 16 to 21, for a use recited in any one of items 1 to 15.
- Item 23 A method for producing cryopreserved bone graft material, comprising the steps of (i) Seeding biological cell material as recited in any one of items 1 to 22 on a scaffold material as recited in any one of items 1 to 22 to obtain a bone graft material, and
- Item 24 The method according to item 23, wherein the bone graft material is cryopreserved in a cryopreservation medium, for example a DSMO containing cryopreservation medium.
- a cryopreservation medium for example a DSMO containing cryopreservation medium.
- Item 25 The method according to item 23 or 24, wherein cryopreservation is at less than -15 °C or less, preferably is -20 °C or less, preferably less than -50 °C (about -70 °C or -80 °C); preferably the cryopreservation comprises a step of freezing at a freezing temperature of less than -20 °C, such as -40 °C or less, and subsequent storing of at temperatures higher than the freezing temperature.
- Item 26 The method according to any one of items 23 to 25, wherein the scaffold material is in granulate form, preferably wherein the granules have an average size of 0.1 to 3 mm, preferably 0.5 to 3 mm, more preferably 0.7 to 2.8 mm, more preferably 1.4 to 2.8 mm.
- Item 27 The method according to any one of items 23 to 26, wherein the biological cell material is seeded on the scaffold material in a density of at least 0.1 x 10 6 cells per mL scaffold material, preferably of at least 0.5 x 10 6 cells per mL scaffold material, more preferably of about 1 x to 6 cells per mL scaffold material.
- Item 28 A method of producing a bone graft implant, the method comprising the step of compressing a bone graft material recited in any one of the preceding items into a tablet, preferably having a height of 1 to 10 mm, preferably 3 to 5 mm, and/ or a diameter of 1 to 15 mm, preferably 5 to 8 mm; the bone graft material not comprising MSC.
- Item 29 A therapeutic kit, comprising
- a first container comprising a scaffold material recited in any one of the preceding items
- a second container comprising a biological cell material recited in any one of the preceding items; wherein the (i) and (ii) are provided in the therapeutic kit in separate containers for combining immediately before surgical insertion; and wherein the kit does not comprise MSC.
- Item 30 The therapeutic kit according to item 29, further comprising two syringes suitable for combining the biological cell material with the scaffold material.
- Item 31 The therapeutic kit according to item 29 or 30, for use in medicine, preferably for use in the treatment of a bone disease or injury, and preferably of osteonecrosis.
- Item 32 A BMDC, or a BMDC preparation, for use in the treatment of a disease, wherein the treatment comprises the administration of the BMDC, or the BMDC preparation, to a subject in need of the treatment by adhering the BMDC or BMDC preparation to a bone graft material to obtain an BMDC -bone graft material, and implanting or attaching the BMDC - bone graft material into/to one or more bone(s) of the patient.
- Item 33 A use of a BMDC, or a BMDC preparation, in the manufacture of a medicament, preferably a bone graft material, for use in the treatment of a bone injury or disorder.
- Figure 1 shows the metabolic activity of cells seeded on b-TCP, frozen and thawed
- FIG. 2 shows a photograph of the tablet of the invention
- MSC were applied at a density of 1x106 cells per cm 3 b-TCP according to established seeding protocols and cultivated for 3h at 37°C and then first frozen at -8o°C (overnight) and then -196°C (7 days) (experimental group). Metabolic activity was determined by MTT test in parallel cultures 24h and 48h after thawing. The control group consisted of MSC seeded at the same density and in the same manner on b-TCP, but incubated for 24h at 37°C only. Subsequently, the metabolic activity was also determined.
- Comparative Example 1 Collection of bone marrow from 8 healthy third-party donors and isolation of BM-MNCs.
- MSCs expressed the typical markers for MSCs, such as CD73, CD90 and CD105 but were negative for hematopoietic cell markers e.g. CD14, CD34, CD45. According to trypan blue staining the viability of these MSCs before freezing was 95 ⁇ 5%.
- the total number of MSCs was distributed in 210 cryovials each containing 1.5x1o 6 MSC Pi and finally frozen in the gaseous phase of liquid nitrogen until use.
- the inventors referred to this set of vials as MSC-bank.
- the MSC as isolated according to comparative example 2 have improved alio suppressive potential as can be derived from WO 2016/008895.
- the scaffold should consist of natural or synthetic matrices e.g. a-TCP, b-TCP, demineralized bone matrix, polylactic acid or polycaprolactone.
- the scaffold should preferably be mechanically stable in order to prevent collapsing during surgical procedures and implantation.
- the scaffold should offer communicating macropores of the size range too pm to 500 pm. Pore sizes from too pm improve angiogenesis, while pore diameters of 300-400 pm have a positive effect on osteoconductivity. Micropores enabling surface enlargement, cellular adhesion and improvement of nutritional support should range fromi pm to 10 pm. Overall porosity of the scaffold should be 60 - 70%, thus ensuring highest possible degree of porosity without compromising the mechanical strength.
- the surface of the material should be rather smooth, rough microstructures in size range 1 - 10 pm should be prevented.
- the surface consists of smooth slightly convex structures with a diameter ranging from 8-15 pm that are arranged in a honey comb similar matter.
- Example 2 Manufacture of a bone implant graft
- MSC derived from the cell bank of comparative example 2 were seeded to the scaffolds as described in Henrich et al, 2009, 2013, 2014; Seebach et al 2010, 2012, 2015. In brief, cells were harvested and preferably adjusted to a density of i*io 6 cells/mL (Range 1 - i*io 7 cells/mL). The cell suspension is carefully dripped on an equal volume of scaffold.
- Cryopreservation will be performed preferably immediately after the seeding procedure but time span between seeding and cryopreservation may vary in a cell type dependent manner from o min to 24hrs. In the latter case the scaffold will be stored in medium (DMEM + 5% platelet lysate) at 37 °C, 5% CO2, 100% humidity until cryopreservation procedure takes place.
- medium DMEM + 5% platelet lysate
- cryopreservation medium preferably consisting of physiologic NaCl solution (65 % v/v, final NaCl concentration 0.7%), human serum albumin solution (HSA, 25% v/v, final HSA concentration 5%) and DMSO (10% v/v).
- the cryopreservation medium is provided in sterile plastic bags. After addition of cell seeded scaffolds (range 1 to 20 scaffolds per bag), the bags are closed by heat sealing. The sealed bags were immediately subjected to a controlled rate freezer. Long term storage will be performed in liquid nitrogen vapor phase. The possibility for short term storage at -30 °C to -20 °C will be analysed. While the example shows the use of MSC, the inventive BMDC preparations work in a similar fashion.
- Example 4 Thawing and use of bone graft implants
- MSC were seeded on approximately 200 pL densely compressed b-TCP granules (size 1.4 -2.8 mm) in a density of i*io 6 cells/mL b-TCP- scaffold.
- the seeding procedure consists of repeated dripping of the cell suspension over the scaffolds during a period of 30 minutes. Subsequently scaffolds were immediately frozen at -80 °C overnight in a medium containing 10% DMSO and 90% FCS.
- As control, MSC on b-TCP (same donor) were cultivated at 37 °C in parallel. All procedures described in the following were also performed with the control approach.
- Metabolic cell equivalent (MCE) of frozen and thawed MSC was 2.7M0 4 and around 25% of MSC cultured at 37 °C on b-TCP (5.8*104 MCE). If MSC were cultured additional 24hrs after thawing, the metabolic activity remained approximately constant (2.6*IO 4 MCE) compared to cell activity directly measured after thawing (2.7M0 4 MCE) whereas the metabolic activity of MSC cultured permanently at 37 °C increased further (1.7M0 5 MCE) compared to the initial value (i.2*io 5 MCE, Figure 1). These results indicate that MSC seeded on a B-TCP scaffold can be stored frozen at -80 °C and remain in part vital. Furthermore, it can be concluded that frozen/thawed MSC did not further deteriorate 24hrs after thawing, though they did not improve either. One might assume that the freeze/thaw procedure induced a lag phase of MSC proliferation.
- MSC-Pool 8 donors, passage 2 was obtained from the Clinic for Pediatrics and Adolescent Medicine. The cells were further cultivated up to a maximum of the 5th passage and used in experiments, or cryopreserved for later experiments. MSC phenotype was activated by FACS analysis (CD90+, CD105+, CD34-, CD45-) and the ability for osteogenic differentiation.
- the metabolic activity of the cells was measured on the day after sowing for the control group and 1 and 2 days after rethawing using the MTT test.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19192114 | 2019-08-16 | ||
PCT/EP2020/073000 WO2021032681A1 (en) | 2019-08-16 | 2020-08-17 | Bone marrow derived cell bone graft material |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4013468A1 true EP4013468A1 (en) | 2022-06-22 |
Family
ID=67659108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20760786.2A Withdrawn EP4013468A1 (en) | 2019-08-16 | 2020-08-17 | Bone marrow derived cell bone graft material |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4013468A1 (en) |
WO (1) | WO2021032681A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2432583A1 (en) | 2002-06-20 | 2003-12-20 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Method of preparing alpha- and beta-tricalcium phosphate powders |
JP2006089311A (en) | 2004-09-22 | 2006-04-06 | Toyo Kohan Co Ltd | Porous beta-tricalcium phosphate body, method for producing the same, and biomaterial |
US20080033572A1 (en) * | 2006-08-03 | 2008-02-07 | Ebi L.P. | Bone graft composites and methods of treating bone defects |
EP2274023B1 (en) * | 2008-04-10 | 2019-12-11 | Bonus Therapeutics Ltd | Bone-like prosthetic implants |
EP2975118B1 (en) | 2014-07-16 | 2016-08-24 | Johann Wolfgang Goethe-Universität, Frankfurt am Main | Generation of a mesenchymal stromal cell bank from the pooled mononuclear cells of multiple bone marrow donors |
US11357890B2 (en) * | 2016-04-01 | 2022-06-14 | New York Stem Cell Foundation, Inc. | Customized hybrid bone-implant grafts |
-
2020
- 2020-08-17 WO PCT/EP2020/073000 patent/WO2021032681A1/en unknown
- 2020-08-17 EP EP20760786.2A patent/EP4013468A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2021032681A1 (en) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Stanovici et al. | Bone regeneration strategies with bone marrow stromal cells in orthopaedic surgery | |
US20200237955A1 (en) | Bioactive Grafts and Composites | |
JP5154729B2 (en) | Porous artificial bone graft and method for producing the same | |
Parikh | Bone graft substitutes in modern orthopedics | |
AU2010328427B2 (en) | Bioactive grafts and composites | |
US6277151B1 (en) | Cartilage growth from cell seeded ceramic compositions | |
JP5759370B2 (en) | Three-dimensional matrix of monetite with structured porosity for tissue engineering and bone regeneration, and method for preparing the three-dimensional matrix | |
JP2012517251A (en) | Bone regeneration material based on monetite and other bioactive calcium composites and silicon compounds | |
US20230084724A1 (en) | Method for producing hydroxyapatite-bioglass materials, said materials and products thereof | |
EP3031479A1 (en) | Compositions for bone reconstruction | |
US9421227B2 (en) | Biomaterials containing calcium phosphate | |
US20220305058A1 (en) | Mesenchymal stromal cell bone graft material | |
BR112012014263B1 (en) | OSTEOCONDUCTIVE ORTOPEDIC FORMAT MEMORY IMPLANT AND MALLEBLE ORTHOPEDIC IMPLANT | |
Daculsi et al. | The micro macroporous biphasic calcium phosphate concept for bone reconstruction and tissue engineering | |
WO2021032681A1 (en) | Bone marrow derived cell bone graft material | |
Daculsi et al. | 20 years of biphasic calcium phosphate bioceramics development and applications | |
Harsini et al. | Bone grafting and the materials for using in orthopedics | |
Goel et al. | Role of tricalcium phosphate implant in bridging the large osteoperiosteal gaps in rabbits | |
US20190151501A1 (en) | Bioactive grafts and composites | |
Ng et al. | Effective cell seeding and three-dimensional cell culture for bone tissue engineering | |
Heymann et al. | Bone substitutes: new concepts | |
US20240024534A1 (en) | Bioactive grafts and composites | |
RU2284788C1 (en) | Method for setting hip joint endoprosthesis pedicle | |
AU2014218483B2 (en) | Bioactive grafts and composites | |
US20200093958A1 (en) | Allografts containing amniotic fluid and methods therof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220315 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230918 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20240130 |